Received Dec 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
pharmacist told her that she received her first Shingrix vaccine in 2022 and 2nd Shingrix vaccine the 22nd of May 2025; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in 2022). On 22-MAY-2025, the patient received the 2nd dose of Shingrix. On 22-MAY-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: pharmacist told her that she received her first Shingrix vaccine in 2022 and 2nd Shingrix vaccine the 22nd of May 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 03-DEC-2025 The patient self-reported this case for herself. The patient stated that she had gone to the pharmacy for her second Shingrix vaccine, and the pharmacist informed her that she had already received both doses of the vaccine. The patient did not recall receiving the first dose and said she was going to review her medical records. The patient did not have any information to identify the vaccines administered and also did not want this health information safety report to be submitted. The batch number was not provided, and unable to contact the reporter.